Streetbeat News

Stock Prices

KYMR

Kymera Therapeutics plans to present new clinical data from its ongoing Phase 1 trial of MDM2 degrader KT-253 at the ASCO meeting. The company will also share its biomarker-based patient selection strategy and future development steps.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:24 pm

FRES

Fresh2 Group has received a delinquency compliance alert notice from Nasdaq, indicating that the company is not in compliance with Nasdaq's listing requirements.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:19 pm

RIGL

Rigel Pharmaceuticals plans to present final five-year results from its Phase 2 trial of REZLIDHIA (olutasidenib) in R/R mIDH1 AML patients at the 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress. The results reinforce the efficacy of REZLIDHIA in heavily pretreated patients.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:15 pm

COGT

Cogent Biosciences has reported updated lead-in data from its ongoing Phase 3 PEAK trial at the ASCO Annual Meeting. The company has accelerated its guidance for the PEAK Phase 3 trial, with enrollment completion now expected in the third quarter of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:09 pm

STEL

Stellar Bancorp has announced a plan to repurchase up to $60 million of its common stock through May 31, 2025. This is an extension of its existing share repurchase program, which allows for repurchases up to $60 million through May 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:03 pm

INAB

IN8bio will present updated results from its fully enrolled Phase 1 study of INB-200 at the ASCO meeting. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for newly diagnosed glioblastoma multiforme (GBM).

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:01 pm

IP

Over the past three months, four analysts have evaluated International Paper (NYSE:IP), with all ratings being bullish. The average 12-month price target has increased to $45.75, reflecting a 20.39% rise from the previous target of $38.00. Despite facing a revenue decline of -7.99% and below-average profitability metrics, analysts have raised their price targets, indicating a positive outlook.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 9:00 pm

CMCSA

DIS

FOXA

WBD

Independent presidential candidate Robert F. Kennedy Jr. has proposed a presidential debate on Elon Musk's platform, X. Musk agreed to host the debate, which would deviate from the traditional televised debate schedule. The current debate schedule includes events on CNN, ABC, NBC, and Fox, all subsidiaries of major media companies.

Portfolio Pulse from Hayden Buckfire

May 23, 2024 | 8:57 pm

DECK

Deckers Outdoor Corp (NYSE:DECK) reported impressive Q4 results, significantly beating analyst estimates for both earnings and sales. The company saw strong growth in its HOKA and UGG brands, while Teva and Sanuk brands experienced declines. DECK shares rose 8.33% in after-hours trading.

Portfolio Pulse from Erica Kollmann

May 23, 2024 | 8:50 pm

ZCMD

Zhongchao Inc has filed for a mixed shelf offering of up to $300 million. This move allows the company to issue various types of securities, including common stock, preferred stock, debt securities, and warrants, over time.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 8:46 pm